193 related articles for article (PubMed ID: 30669306)
1. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples.
O'Brien O; Wright MC; O'Brien C; Geoghegan O; Leonard N; Nicholson S; Cuffe S; Fabre A; Jochum W; Joerger M; Gray SG; Finn SP
Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30669306
[TBL] [Abstract][Full Text] [Related]
2. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
Sui JSY; Finn SP; Gray SG
Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
[TBL] [Abstract][Full Text] [Related]
3. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
4. An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples.
Bironzo P; Pepe F; Russo G; Pisapia P; Gragnano G; Aquino G; Bessi S; Buglioni S; Bartoccini F; Ferrero G; Bresciani MA; Francia di Celle P; Sibona F; Giusti A; Movilia A; Farioli RM; Santoro A; Salemi D; Scarpino S; Galafate D; Tommasi S; Lacalamita R; Seminati D; Sajjadi E; Novello S; Pagni F; Troncone G; Malapelle U
Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832117
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
Das R; Jakubowski MA; Spildener J; Cheng YW
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230737
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
7. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
8. Detection of
Subramanian J; Tawfik O
Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
[No Abstract] [Full Text] [Related]
9. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
[TBL] [Abstract][Full Text] [Related]
12. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
13. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
14. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
[TBL] [Abstract][Full Text] [Related]
15. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.
Mahrous M; Omar Jebriel A; Allehebi A; Shafik A; El Karak F; Venturini F; Alhusaini H; Meergans M; Ali Nahit Sendur M; Ouda M; Al-Nassar M; Kilickap S; Al Turki S; Al-Fayea T; Abdel Kader Y
Cureus; 2023 Jul; 15(7):e41992. PubMed ID: 37492039
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with
Digumarthy SR; Mendoza DP; Zhang EW; Lennerz JK; Heist RS
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861060
[No Abstract] [Full Text] [Related]
17. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
Minne RL; Luo NY; Traynor AM; Huang M; DeTullio L; Godden J; Stoppler M; Kimple RJ; Baschnagel AM
Clin Lung Cancer; 2024 May; ():. PubMed ID: 38852006
[TBL] [Abstract][Full Text] [Related]
18. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
[TBL] [Abstract][Full Text] [Related]
20. Characterization of
Kim SY; Yin J; Bohlman S; Walker P; Dacic S; Kim C; Khan H; Liu SV; Ma PC; Nagasaka M; Reckamp KL; Abraham J; Uprety D; Wang F; Xiu J; Zhang J; Cheng H; Halmos B
JTO Clin Res Rep; 2022 Sep; 3(9):100381. PubMed ID: 36082279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
